Waterside Pharmaceuticals
Revolutionising the medicinal cannabis industry in the UK using Total Controlled Environment Agriculture.
About Us: Cultivating a Better Future
We are Waterside Pharmaceuticals, a dynamic team with extensive experience in highly regulated industries, united in our mission to revolutionise medicinal cannabis cultivation in the UK.
Founded by Martin Dickie, co-founder of BrewDog, our in-house expertise ranges from quality assurance, law, finance, cultivation and engineering in the food & drinks, energy and pharmaceutical industries. We are passionate about ensuring patient safety whilst delivering exceptional quality, and sustainable practices.
​
Committed to making a positive impact on both people and the planet, we adhere to the highest GACP, GMP and GDP standards while pushing boundaries in the medicinal cannabis industry. We are on a mission to convert our existing TCEA (Total Controlled Environment Agriculture) vertical farming facility to the first of its kind in the UK.
Our Mission: Champions of Excellence
Our mission is to revolutionise the UK cannabis cultivation industry. We prioritise cultivation, sanitation, traceability, replicability and quality control. By surpassing industry standards and following Good Agriculture and Collection Practice (GACP), Good Manufacturing Practices (GMP) and Good Distribution Practice (GDP), we strive for excellence through continuous improvement.
Our Total Controlled Environment Agriculture (TCEA) facility ensures optimal growing conditions, resulting in consistently superior products. We employ sustainable practices without the use of pesticides or fungicides. We invest in our team’s development to foster expertise and passion, empowering them to drive innovation and maintain high standards.
We prioritise cultivation, sanitation, traceability, replicability, sustainability and quality control and will be operating to international pharmaceutical standards, following Good Agriculture and Collection Practice (GACP), Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP). We will be striving for excellence through continuous improvement within a rigorous Pharmaceutical Quality Management System.
​
We are focused on championing excellence in the sector and are committed to delivering premium products that surpass expectations, ensuring patient safety is at the forefront of everything we do.